Delay in Diagnostic Workup and Treatment of Esophageal Cancer by Grotenhuis, Brechtje A. et al.
ORIGINAL ARTICLE
Delay in Diagnostic Workup and Treatment of Esophageal Cancer
Brechtje A. Grotenhuis & Pieter van Hagen &
Bas P. L. Wijnhoven & Manon C. W. Spaander &
Hugo W. Tilanus & Jan J. B. van Lanschot
Received: 15 September 2009 /Accepted: 9 November 2009 /Published online: 10 December 2009
# 2009 The Author(s). This article is published with open access at Springerlink.com
Abstract
Introduction Esophageal cancer should preferably be detected and treated at an early stage, but this may be prohibited by
late onset of symptoms and delays in referral, diagnostic workup, and treatment. The aim of this study was to investigate the
impact of these delays on outcome in patients with esophageal cancer.
Methods For 491 patients undergoing esophagectomy for cancer between 1991 and 2007, patients’ short- and long-term
outcome were analyzed according to different time intervals between onset of symptoms, diagnosis, and surgical
treatment.
Results Length of prehospital delay (from onset of symptoms until endoscopic diagnosis) did not affect patient’s short- or
long-term outcome. A shorter hospital delay between establishing the diagnosis of esophageal cancer on endoscopy and
surgery was associated with lower overall morbidity and in-hospital mortality. Patients of ASA classes I and II experienced
a shorter hospital delay than patients of ASA classes III and IV. Length of hospital delay between endoscopic diagnosis and
surgery did not affect pathological tumor–node–metastasis stage or R0-resection rate. Longer hospital delay did not result in
worse survival: Overall survival after esophagectomy for cancer was not significantly different between patients with
hospital delay <5, 5–8, or >8 weeks (24.7%, 21.7%, and 32.3%, respectively; p=0.12).
Conclusion A longer hospital delay (between endoscopic diagnosis and surgery) resulted in worse patient’s short-term
outcome (higher overall morbidity and mortality rates) but not in a worse long-term outcome (overall survival). This may be
explained by a more time-consuming diagnostic workup in patients with a poorer physical status and not by tumor
progression.
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Introduction
The 5-year survival rate for esophageal cancer patients after
esophagectomy with curative intent has improved up to
40%.
1–3 As further improvement in survival from a single
modality approach, such as surgery, is unlikely, consider-
able interest has grown in other strategies that may improve
patients’ survival (neoadjuvant chemo- and/or radiotherapy
in particular). In many types of cancer, the prognosis of
patients with small, localized tumors is better than with
locally advanced or metastatic disease. Similar to other
malignancies such as colorectal and breast cancer, the
outcome of esophageal cancer is related to the pathological
tumor–node–metastasis (pTNM) stage of the disease.
2,4,5
Therefore, detection and treatment of esophageal cancer at
an early stage could also improve long-term survival.
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DOI 10.1007/s11605-009-1109-yEarly detection of esophageal cancer may be prohibited
not only by the late onset of symptoms but also by delays in
referral to an appropriate specialist, establishment of the
diagnosis, further diagnostic workup, and start of treatment.
However, the impact of these delays on both short- and
long-term outcome for patients undergoing esophagectomy
for cancer is unclear.
In patients with breast cancer, delays of 3–6 months
between the onset of symptoms and start of treatment are
associated with lower survival, caused by a more advanced
tumor stage.
6 In two systematic reviews, no association was
found between diagnostic and therapeutic delay and
survival in colorectal cancer patients
7 nor between these
delays and disease stage.
8 A few studies have investigated
the impact of delays in diagnosis and treatment of
esophageal cancer. Drawbacks of these studies are small
numbers of patients included,
9 analyses that do not cover
the complete track between onset of symptoms and surgical
treatment,
10,11 combined patient groups with gastric and
esophageal carcinoma,
12,13 and studies lacking survival
analyses.
9,11–13
We hypothesized that longer delays between onset of
symptoms, endoscopic diagnosis, and surgical treatment are
associated with a worse short-term outcome (morbidity,
reoperation rate, and in-hospital mortality), worse tumor
stage, and hence, worse long-term outcome (overall
survival) following potentially curative esophagectomy in
patients with esophageal cancer.
Patients and Methods
The Erasmus Medical Center in Rotterdam is a tertiary
referral center for patients with esophageal cancer in The
Netherlands. Most patients are referred to the Erasmus MC
outpatient clinic for (surgical) treatment after the diagnosis
of esophageal cancer has been established in a referring
hospital (group A). The minority of patients is directly
referred by the general practitioner (GP) to the Erasmus
MC for clinical investigations of symptoms suggestive of
cancer (group B). In all patients (groups A and B) upper
gastrointestinal endoscopy with biopsy is (re)done in the
Erasmus MC to confirm the diagnosis of esophageal cancer
and to determine the exact location of the tumor. Staging is
performed routinely with endoscopic ultrasonography, CT
scanning of thorax and abdomen, and external ultrasound of
the neck. Every patient is discussed in a weekly multidis-
ciplinary oncology meeting in which a definitive treatment
plan is designed. If eligible for surgery, patients are put on
the waiting list for surgery. On the same day, the patient is
referred to the Department of Anesthesiology for preoper-
ative counseling. If needed, additional cardiac and/or
pulmonary function tests are scheduled.
Between January 1991 and December 2007, 791 patients
underwent esophagectomy for cancer of the esophagus or
gastroesophageal junction in the Erasmus MC. To obtain a
homogeneous cohort of patients in terms of treatment and
to circumvent possible stage migration following chemo-
and/or radiotherapy, patients receiving (neo)adjuvant
therapy were excluded from this analysis. In our hospital,
patients received neoadjuvant chemo(radio)therapy in the
context of randomized controlled trials.
14,15 Induction
chemo- and/or radiotherapy was given in patients with
either a cT4 tumor without distant metastases or in patients
with gross involvement of celiac trunk lymph nodes (M1a),
who were not considered eligible for primary surgical
therapy. There were 214 patients who were excluded
because of chemo- and/or radiotherapy prior to surgery. In
44 patients, the hospital delay from endoscopic diagnosis to
surgery could not be calculated, as the date of their first
upper gastrointestinal endoscopy performed in the referring
hospital was unknown. Another 42 patients were excluded,
as they participated in a Barrett’s esophagus surveillance
program. Over recent years, multiple attempts for endo-
scopic treatment of early lesions delayed referral to the
Department of Surgery in such way that this group was not
representative for patients treated for (more advanced)
esophageal cancer. Finally, data of 491 patients were
analyzed in the present study. The vast majority of these
patients underwent a transhiatal esophagectomy with
locoregional lymphadenectomy only (N=477). In 14
patients, a transthoracic resection with extended lymphade-
nectomy was performed. The applied surgical techniques
have been described previously.
3,16 Tumors were assigned
pTNM stages according to the Union Internationale Contre
le Cancer 2002 system.
17
Data on patients’ demographics, diagnostic tests, sur-
gery, postoperative morbidity, in-hospital mortality, and
survival have been collected prospectively and stored in a
database by a data manager. From this database, the
following time points were defined:
– Date of upper gastrointestinal endoscopy in the
referring hospital, on which the diagnosis of esopha-
geal cancer had been established by histology from
biopsies (only applicable for group A)
– Date of first visit at the Erasmus MC outpatient clinic:
Department of Surgery, Gastroenterology, or Medical
Oncology
– Date of upper gastrointestinal endoscopy in the
Erasmus MC, on which the diagnosis of esophageal
cancer had been established by histology from biopsies
– Date of the multidisciplinary oncology meeting, after
which the patient had been put on the operative waiting
list if eligible for surgery
– Date of surgery.
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marked in the process between onset of symptoms and
surgery, we divided this time span into two major time
intervals that have been analyzed separately: pre-hospital
and hospital delay (see Fig. 1). Subsequently, data were
analyzed in three different ways:
– Impact of prehospital delay: time from onset of
symptoms until diagnosis on first endoscopy (either in
the referring hospital for group A or in Erasmus MC
for group B)
– Impact of hospital-delay: time from diagnosis on
patient’s first endoscopy undertaken until surgery
– Impact of specific time intervals between diagnosis on
first endoscopy and surgery. In order to examine the
hospital-delay in more detail, the effect of specific time
intervals between diagnosis in the referring hospital,
first visit at the outpatient clinic in Erasmus MC,
diagnosis on endoscopy in Erasmus MC, multidisci-
plinary oncology meeting, and surgery on short- and
long-term outcome were analyzed. For this purpose,
only data from patients in group A were used.
Statistics
Follow-up was recorded until December 2008 or until death
if earlier and was complete for all patients. Statistical
analysis for non-parametric data was used. Grouped data
were compared using the chi-square, Mann–Whitney U,o r
Kruskall–Wallis H test. Patients who died due to compli-
cations following esophagectomy (in-hospital mortality)
were not excluded from survival analysis. Overall survival
was calculated from the date of operation until the date of
last follow-up or death according to the Kaplan–Meier
method. Disease-free survival was assessed from the date of
operation until the date of disease recurrence in case of
locoregional recurrence or distant metastases. Univariate
analyses were performed with the log-rank test to identify
prognostic variables associated with overall survival after
esophagectomy. Data analyses were carried out with SPSS
version 15.0 (SPSS, Chicago, IL, USA).
Results
Patients’ characteristics are shown in Table 1.T h r e e
hundred sixty-five patients (74.3%), in whom the diagnosis
esophageal cancer was established in another hospital, were
referred to the Erasmus MC for further staging and
treatment (group A). One hundred twenty-six patients
(25.7%) were referred directly to the Erasmus MC by the
general practitioner for investigation of symptoms sugges-
tive of esophageal cancer (group B). Patients’ first visit to
the Erasmus MC was at the Department of Surgery (N=
338, 68.8%), Department of Gastroenterology (N=147,
29.9%), or Department of Medical Oncology (N=6, 1.3%).
Impact of Prehospital Delay: Time from Onset
of Symptoms Until First Endoscopy
The majority of patients underwent endoscopy for investiga-
tion of obstructive symptoms suggestive of cancer like
dysphagia, odynophagia, and weight loss (N=462, 94.1%).
Other indications for endoscopy encompassed investigation
of hematemesis (N=12, 2.4%), anemia (N=9, 1.8%), or
melena (N=8, 1.6%). Prehospital delay (from onset of
symptoms until first endoscopy) lasted a median time period
of 3.0 months (range, 0–36 months). Patient’ss h o r t - t e r m
(morbidity, reoperation rate, and in-hospital mortality) and
long-term outcome (overall 5-year survival) after esophagec-
tomy were comparable for patients who experienced
  
Onset of symptoms Diagnosis on endoscopy: 
-referring hospital (group A) 
-Erasmus MC (group B)
Multidisciplinary
oncology meeting 
Surgery
PREHOSPITAL-DELAY HOSPITAL-DELAY
Figure 1 Analysis of prehospital and hospital delays encountered by
patients who underwent surgical resection for esophageal cancer in
Erasmus MC.
Table 1 Clinicopathological Characteristics of 491 Patients who
Underwent Surgical Resection for Esophageal Cancer and Who Were
Included in the Present Study
Age (in years)
a 65 (28–89)
Gender
Male 399 (81.3%)
Female 92 (18.7%)
ASA classification
I 77 (15.7%)
II 316 (64.4%)
III 96 (19.6%)
IV 2 (0.4%)
Tumor location
Proximal esophagus 8 (1.6%)
Mid esophagus 27 (5.5%)
Distal esophagus 196 (39.9%)
Gastroesophageal junction 260 (53.0%)
Histology
Squamous cell carcinoma 73 (14.9%)
Adenocarcinoma 418 (85.1%)
ASA classification American Society of Anesthesiologists classification
aAge is given as median (range)
478 J Gastrointest Surg (2010) 14:476–483symptoms for a period of 3 months or less versus more than
3 months until endoscopy was performed (Table 2).
Impact of Hospital Delay: Time from Endoscopic
Diagnosis Until Surgery
The hospital delay from establishing the diagnosis of
esophageal cancer on endoscopy (either in the referring
hospital for group A or in Erasmus MC for group B) until
surgery was 49 days (given as median, range of 5–
175 days). This delay encompassed a median time period
of 28 days (range, 0–147 days) from diagnosis on patient’s
first endoscopy until the multidisciplinary oncology meet-
ing (staging delay), and a median time period of 15 days
from this meeting until surgery (operative waiting list,
range of 1–67 days). Median hospital delay between
diagnosis and surgery increased during the study period
(1991–2007): 3.9 weeks in 1991 toward 10.9 weeks in
2007 (Fig. 2). This increase in hospital delay should rather
be ascribed to the 3.4 times increase in length of the
operative waiting list (1.6 weeks in 1991 towards 5.6 weeks
in 2007) than to the 1.5 times increase in staging delay
(3.3 weeks in 1991 towards 4.9 weeks in 2007).
A shorter hospital delay between establishing the
diagnosis of esophageal cancer on patient’s first endoscopy
and surgery was associated with significantly lower overall
morbidity and mortality (Table 3). These associations
appeared to be linear: morbidity (p=0.001) and in-hospital
mortality (p=0.01) increased with longer hospital delay.
Patients of ASA classes I and II experienced a shorter
hospital delay than patients of ASA classes III and IV
(hospital delay <5 weeks, 28.8%; 5–8 weeks, 36.9%; and
>8 weeks, 34.4% versus <5 weeks, 15.3%; 5–8 weeks,
41.8%; and > 8 weeks, 42.9%, respectively; p=0.02).
Length of hospital delay did not affect pTNM stage or R0-
resection rate (Table 3).
Longer hospital delay did not result in worse survival
(Fig. 3): Overall 5-year survival was 24.7% in patients with
a hospital delay less than 5 weeks, 21.7% in patients with a
hospital delay between 5 and 8 weeks and 32.3% in patients
in whom the hospital delay was more than 8 weeks.
Although overall survival appeared to be longer in patients
with a longer hospital delay, this difference was not
statistically significant (p=0.12). Parameters found to be
associated with overall survival in univariate analyses are
shown in Table 4: age younger than 65 years, early pTstage
(pT1 or pT2), no lymph node involvement (pN0), absence
of distant metastatic disease (pM0), good differentiation
grade of the tumor, R0 resection, and lymph node ratio
smaller than 0.24 were favorable of improved overall
survival. Survival analysis with regard to 5-year disease-
free survival paralleled the overall 5-year survival curves
(27.0%, 27.7%, and 38.3%, respectively; p=0.09).
Impact of Specific Time Intervals Between Endoscopic
Diagnosis and Surgery (Group A)
The median hospital delay was 53 days (range, 5–
175 days) for patients in group A in whom the diagnosis
esophageal cancer had been established in another hospital
and who were referred to the Erasmus MC for surgical
treatment (N=365). The breakdown of this delay is shown
in Table 5, according to the different time intervals
between diagnosis in the referring hospital, first visit to
the outpatient clinic in Erasmus MC, diagnosis on
endoscopy in Erasmus MC, multidisciplinary oncology
meeting, and surgery.
When analyzing the impact of the separate time
intervals, it appeared that the delay between the multidis-
ciplinary oncology meeting and surgery (median, 15 days;
reflecting the length of the operative waiting list) was the
only time interval that influenced short-term outcome post-
Figure 2 Median hospital delay (in weeks) between endoscopic
diagnosis and surgery increased during the study period (1991–2007):
3.9 weeks in 1991 toward 10.9 weeks in 2007.
Prehospital delay ≤3months,
N=308
Prehospital delay >3months,
N=183
p value
Morbidity 199 (64.6%) 104 (56.8%) 0.09
Reoperation 34 (11.0%) 16 (8.7%) 0.42
In-hospital mortality 18 (5.8%) 9 (4.9%) 0.66
Overall 5-year survival 24.0% 29.3% 0.10
Table 2 Impact of Prehospital
Delay from Onset of Symptoms
to First Endoscopy on Short-
and Long-Term Outcome After
Esophagectomy; Comparison
of Prehospital Delay ≤3 Months
(N=308) Versus >3 Months
(N=183)
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parable between patients who had been on the waiting list
for 15 days or shorter versus patients who were waiting for
more than 15 days (p=0.14), length of the operative waiting
list did influence morbidity (55.7% versus 67.1%, p=0.03),
and a trend towards an increased reoperation rate could be
noted (7.8% versus 13.9%, p=0.06). However, in contrast
with the hospital delay between endoscopic diagnosis and
surgery, none of the separate time intervals affected long-
term survival.
Table 3 Impact of the Hospital Delay from Diagnosis on Patient’s First Endoscopy Until Surgery: Hospital Delay <5 Weeks (N=128), 5–8 Weeks
(N=186), and >8 Weeks (N=177)
Delay <5weeks, N=128 Delay 5–8weeks, N=186 Delay >8weeks, N=177 p value
Morbidity 62 (48.4%) 122 (65.6%) 119 (67.2%) <0.01
In-hospital mortality 2 (1.6%) 10 (5.4%) 15 (8.5%) 0.03
Reoperation 7 (5.5%) 20 (10.8%) 23 (13.0%) 0.10
pT stage
pT1–pT2 30 (23.4%) 57 (30.6%) 54 (30.5%) 0.31
pT3–pT4 98 (76.6%) 129 (69.4%) 123 (69.5%)
pN stage
pN0 42 (32.8%) 66 (35.5%) 62 (35.0%) 0.88
pN1 86 (67.2%) 120 (64.5%) 115 (65.0%)
pM stage
pM0 103 (80.5%) 150 (80.6%) 131 (74.0%) 0.24
pM1a–M1b 25 (19.5%) 36 (19.4%) 46 (26.0%)
Radicality of resection
R0 86 (67.2%) 124 (66.7%) 130 (73.4%) 0.32
R1–R2 42 (32.8%) 62 (33.3%) 47 (26.6%)
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Figure 3 Overall 5-year survival for esophageal cancer patients
appeared longer for patients with a hospital delay between diagnosis
on first endoscopy and surgery >8 weeks (N=177) versus patients
with a hospital delay <5 weeks (N=128) or 5–8 weeks (N=186),
although this difference did not reach statistical significance (p=0.12).
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When initiating the current study, we hypothesized that
longer delays between onset of symptoms, diagnosis, and
surgical treatment are associated with worse short-term
outcome (in terms of morbidity, reoperation rate, and
mortality) and worse long-term outcome (overall survival)
following esophagectomy for cancer. In the present series,
it appeared that length of prehospital delay (from onset of
symptoms until endoscopic diagnosis) did not influence
patient’s short-term outcome or overall 5-year survival.
Onset of symptoms is a subjective measurement, and it may
be that patients are not able to recall the exact moment that
they first experienced discomfort. Furthermore, although
little information is known about the tumor doubling time
of esophageal cancer, the period of time in which a patient
is symptomatic may be relatively short when compared to
the total period between the first presence of malignant
cells in the esophagus and the diagnosis of esophageal
cancer. Unfortunately, we did not have information on
delays caused by the GP (i.e., time between onset of
symptoms and referral for endoscopy). Nevertheless, we do
want to emphasize the importance of both patient and
primary care education that will result in earlier notification
of alarming symptoms such as dysphagia and weight loss.
A longer hospital delay from endoscopic diagnosis until
surgery was associated with higher overall morbidity and
mortality. This could be explained by a more thorough and
time-consuming diagnostic workup in patients with a
poorer physical status. Indeed, in the present study, patients
of ASA classes I and II experienced a shorter hospital delay
than patients of ASA classes III and IV. Alternatively, a
longer delay prior to surgery may also have caused a worse
physical status in esophageal cancer patients by means of
malnutrition. However, this remains speculative, as our
database did not provide detailed information with regard to
patients’ preoperative nutritional status (e.g., nutritional risk
indices). When analyzing the impact of the separate time
intervals between patient’s first endoscopy and surgery, it
appeared that the length of the operative waiting list was
the time interval that influenced short-term outcome
following esophagectomy the most. From the literature, it
Table 4 Univariate Analyses of Potential Prognostic Variables Asso-
ciated with Overall Survival After Esophagectomy for Cancer (N=491)
Variable Five-year survival (%) p value
Age
≤65 years 30.2 0.001
>65 years 21.4
Sex
Male 25.4 0.84
Female 28.5
ASA classification
I–II 27.0 0.12
III–IV 22.2
pT stage
pT1–T2 53.3 <0.001
pT3–T4 15.0
pN stage
pN0 50.3 <0.001
pN1 12.2
pM stage
pM0 39.8 <0.001
pM1a–M1b 9.5
Histology
Squamous cell carcinoma 27.1 0.98
Adenocarcinoma 25.8
Differentiation grade of tumor
Good 69.1
Moderate 29.5 <0.001
Poor 16.0
Radicality of resection
R0 35.5 <0.001
R1–R2 5.5
Lymph node ratio
≤0.24 36.0 <0.001
>0.24 12.0
Referral
By another hospital (group A) 25.9 0.65
By GP (group B) 26.2
Prehospital delay
≤3 months 24.0 0.10
>3 months 29.3
Hospital delay
<5 weeks 24.7
5–8 weeks 21.7 0.12
>8 weeks 32.3
ASA classification American Society of Anesthesiologists classifica-
tion, GP general practitioner
Table 5 Delays Encountered by Esophageal Cancer Patients who
have been Referred from an Other Hospital to the Erasmus MC for
Surgical Treatment (group A, N=365)
Diagnosis on endoscopy elsewhere→
first visit outpatient clinic Erasmus MC
17 days (1–138)
First visit outpatient clinic Erasmus MC→
diagnosis on endoscopy Erasmus MC
6 days (0–36)
Diagnosis on endoscopy Erasmus MC→
multidisciplinary oncology meeting
7 days (0–95)
Multidisciplinary oncology meeting→surgery 15 days (1–67)
Total hospital delay
Diagnosis on endoscopy elsewhere→surgery 53 days (5–175)
Lengths of delays are given as a median values with the corresponding
range in brackets
J Gastrointest Surg (2010) 14:476–483 481is also known that the quality of life in newly diagnosed
esophageal cancer patients who are waiting for surgery is
seriously impaired.
18 Hence, it should be aimed for to keep
this time interval to a minimum.
Our second hypothesis was that patients with longer
delays would generally present with more advanced disease
and that this relation between delay and stage would result
in a poorer survival. However, pTNM stages were
comparable in patients with a hospital delay <5, 5–8, or
>8 weeks between endoscopy and surgery. Surprisingly, it
appeared that overall survival was improved in patients
with a longer hospital delay, although this difference was
not statistically significant. This is in line with the results of
Kötz et al.
10 who showed that a longer delay between
diagnosis and surgical resection was associated with
improved survival in esophageal cancer patients. However,
the delay between diagnosis and surgery was not an
independent prognostic variable on multivariate analysis
in their study. Kötz et al.
10 noted that patients with a longer
delay had a higher rate of complete tumor resection,
suggesting that they were more appropriately selected for
surgical treatment. In our series, we could not find evidence
that patients were selected more appropriately, as both
pTNM stage and R0-resection rate did not differ between
patients with a shorter or longer hospital delay. However,
hospital delay substantially increased especially over the
last few years in our hospital (Fig. 2). This can probably
explain the counter-intuitive correlation between longer
hospital delay and improved long-term survival, which is
rather reflecting state-of-the-art staging modalities, refined
surgical techniques, and improved intensive care that have
been introduced over the past years. Theoretically, it could
also be possible that, in our hospital, patients did not
undergo surgery anymore after a longer hospital delay in
case the tumor progressed to a stage that was considered
irresectable. However, in our patient group, the increased
hospital delay can rather be ascribed to an increase in
length of the operative waiting list than to an increased
staging delay. As the decision on whether to operate or not
has been made during the multidisciplinary oncology
meeting, it is unlikely that a longer hospital delay led to a
dropout of patients with irresectable tumors and, hence, a
more selected patient group that underwent esophagectomy.
It is evident that efforts are taken to minimize delays
experienced by patients with esophageal cancer between
onset of symptoms, diagnosis, and surgical treatment. The
National Health Service cancer plan was implemented in
2000 in the UK, indicating that all patients with relevant
symptoms and suspected cancer should be able to see a
specialist within 2 weeks of their GP referral. The
introduction of these guidelines was associated with
reductions in times to first outpatient visit, endoscopy, and
diagnosis in patients with upper gastrointestinal cancer
(esophageal or gastric).
19,20 However, the effectiveness of
the NHS cancer plan is uncertain, as it can be questioned
whether the slightly improved survival rates after 2000 can
be ascribed to this plan.
21
In our hospital, we recently introduced a new schedule
of diagnostic services for patients with suspected esopha-
geal cancer. It is attempted to see patients at the outpatient
clinic of the Department of Surgery or Department of
Gastroenterology within 1 week after referral. Furthermore,
patients are offered all imaging modalities in 1 week,
including upper gastrointestinal endoscopy, endoscopic
ultrasonography, CT scanning of thorax and abdomen, and
external ultrasound of the neck. The aim of this schedule is
to minimize the delay between referral to our hospital and
establishment of a definitive treatment plan for each
individual patient.
In conclusion, length of prehospital delay (from onset of
symptoms until diagnosis) did not affect patient’s short- or
long-term outcome. A longer hospital delay (between
endoscopic diagnosis and surgery) resulted in worse
patient’s short-term outcome (higher overall morbidity and
mortality rates) but not in worse long-term outcome (overall
s u r v i v a l ) .T h i sm a yb ee x p l a i n e db yam o r et i m e -
consuming diagnostic workup in patients with a poorer
physical status and not by tumor progression.
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